SOURCE: Hendrx Corp.

March 06, 2006 08:00 ET

Hendrx Made Party to Contract and Patent Infringement Suit

VANCOUVER, BC -- (MARKET WIRE) -- March 6, 2006 -- Hendrx Corp. (OTC BB: HDRX) ("Hendrx") announced today that legal proceedings have been initiated by Worldwide Water, LLC ("WWL") against a number of defendants, including Hendrx, in the Superior Court for the County of Los Angeles, State of California, for breach of contract and patent infringement.

The complaint alleges that an agreement between WWL and AirWater Corporation ("AirWater") was contravened when AirWater contracted with Fujian Yuxin Electronic Equipment Co. Ltd ("Yuxin"), a wholly owned subsidiary of Hendrx, to manufacture atmospheric water generators ("AWGs"), on an original equipment manufacturer (OEM) basis, that infringe WWL's patents. WWL's suit seeks damages of $1,000,000 from the defendants in addition to accrued interest and costs. Hendrx denies any culpability or liability in this matter and believes that it will ultimately succeed in defending the merits of this position.

ABOUT HENDRX CORP.

Hendrx is engaged in the research, development, manufacture, marketing and worldwide distribution of water generation, filtration, ionization, and purification devices. Hendrx's products include AWG units, Alkaline Calcium Ionic Water Dispensers, Reverse Osmosis ("RO") devices and RO under sink systems, as well as carbon filtration devices.

AWG 'self-contained' products extract moisture from the atmosphere and transform it into pure, healthy, drinking water with no plumbing hook-ups or water lines. This technology taps into a virtually unlimited supply of water from the atmosphere and creates clean potable water that meets or surpasses international water quality standards. Current distribution to over 40 countries worldwide targets the residential, commercial, industrial, government and humanitarian markets.

For investor, product or corporate info, visit their website at www.hendrxcorp.com, email Hendrx at info@hendrxcorp.com, or call 1-877-HENDRX-1.

CAUTIONARY STATEMENTS

The opinions and statements contained herein are accurate as of the date on which same are made, are not guarantees of future outcomes which may involve numerous and certain risks, uncertainties or assumptions that are difficult to predict, and many or most of which may be beyond the control or influence of the management at Hendrx. Therefore, actual outcomes and results could materially differ from what is expressed, implied, or forecast in such forward-looking statements.

Hendrx assumes no obligation to update the information contained in this press release. Hendrx's future results may be impacted by risks associated with rapid technological change, new product introductions, existing or new competition, new technological developments and implementations, managing growth, execution issues associated with new technology and product developments and enhancements, ramping manufacturing production to meet demand, our working capital needs and access to such working capital, potential fluctuations in quarterly operating results, adjustments to these amounts which may be reflected in our quarterly filings, competition, financial and budgetary constraints of prospects and customers, international order delays, dependence upon sole and limited source suppliers, any future unknown governmental inquiries and investigations, fluctuations in component pricing, government regulations, distributor performance and results, dependence upon key employees, and our ability to retain employees. Hendrx's future results may also be impacted by other risk factors listed from time to time in its filings with the Securities and Exchange Commission, including, but not limited to, Hendrx's Annual Report on Form 10-KSB and Quarterly Reports on Form 10-QSB. Hendrx's public filings may be viewed at www.sec.gov.

The statements made herein are independent statements made solely by management of Hendrx. The inclusion of any third parties does not represent an endorsement of any Hendrx products or services by any such third parties.

Contact Information

  • CONTACT

    Hendrx Corp.

    Bruce Nurse
    Investor Relations
    1-877-HENDRX-1 (1-877-436-3791)
    email: info@hendrxcorp.com